206 related articles for article (PubMed ID: 8944206)
1. New treatments for patients with type 2 diabetes mellitus.
Wolffenbuttel BH; Graal MB
Postgrad Med J; 1996 Nov; 72(853):657-62. PubMed ID: 8944206
[TBL] [Abstract][Full Text] [Related]
2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
3. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
Hermansen K; Mortensen LS
Drug Saf; 2007; 30(12):1127-42. PubMed ID: 18035865
[TBL] [Abstract][Full Text] [Related]
4. New pharmacological development (alpha glucosidase inhibitors, amylin analogues, GLP-1, thiozolidinediones, short acting insulin analogues).
Dharmalingam M; Kumar P
J Assoc Physicians India; 2001 Jan; 49 Spec No():46-9. PubMed ID: 11235605
[No Abstract] [Full Text] [Related]
5. The use of insulin secretagogues in the treatment of type 2 diabetes.
Luna B; Hughes AT; Feinglos MN
Prim Care; 1999 Dec; 26(4):895-915. PubMed ID: 10523467
[TBL] [Abstract][Full Text] [Related]
6. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity.
Purnell JQ; Weyer C
Treat Endocrinol; 2003; 2(1):33-47. PubMed ID: 15871553
[TBL] [Abstract][Full Text] [Related]
7. Recent developments and emerging therapies for type 2 diabetes mellitus.
Evans AJ; Krentz AJ
Drugs R D; 1999 Aug; 2(2):75-94. PubMed ID: 10820647
[TBL] [Abstract][Full Text] [Related]
8. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
Baron AD; Kim D; Weyer C
Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
[TBL] [Abstract][Full Text] [Related]
9. Treatments and devices for future diabetes management.
Capaldi B
Nurs Times; 2005 May 3-9; 101(18):30-2. PubMed ID: 15892503
[TBL] [Abstract][Full Text] [Related]
10. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological management of type 2 diabetes mellitus: an update.
El-Kaissi S; Sherbeeni S
Curr Diabetes Rev; 2011 Nov; 7(6):392-405. PubMed ID: 21846326
[TBL] [Abstract][Full Text] [Related]
12. [The role of incretins. Type 2 diabetes with new beginnings].
MMW Fortschr Med; 2005 Mar; 147(10):48-9. PubMed ID: 15803785
[No Abstract] [Full Text] [Related]
13. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
14. Islet adaptation to insulin resistance: mechanisms and implications for intervention.
Ahrén B; Pacini G
Diabetes Obes Metab; 2005 Jan; 7(1):2-8. PubMed ID: 15642070
[TBL] [Abstract][Full Text] [Related]
15. Novel pharmacologic agents for type 2 diabetes.
Uwaifo GI; Ratner RE
Endocrinol Metab Clin North Am; 2005 Mar; 34(1):155-97. PubMed ID: 15752927
[TBL] [Abstract][Full Text] [Related]
16. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
17. Oral antidiabetic drugs: an overview.
Melander A
Diabet Med; 1996 Sep; 13(9 Suppl 6):S143-7. PubMed ID: 8894498
[TBL] [Abstract][Full Text] [Related]
18. Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data.
Kruger DF; Gloster MA
Drugs; 2004; 64(13):1419-32. PubMed ID: 15212559
[TBL] [Abstract][Full Text] [Related]
19. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
20. [New strategy in type 2 diabetes tested in clinical trials. Glucagon-like peptide 1 (GLP-1) affects basic caused of the disease].
Ahrén B
Lakartidningen; 2005 Feb 21-27; 102(8):545-9. PubMed ID: 15786905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
